Drugs / LTT462
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04294160 | Jul 2020 → Sep 2024 | colorectal cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02974725 | Feb 2017 → Apr 2024 | melanoma, non-small cell lung carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02711345 | Apr 2016 → Nov 2018 | melanoma, non-small cell lung carcinoma, ovarian neoplasm | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04417621 | Oct 2020 → Feb 2027 expected | melanoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LTT462 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02711345 ↗ |
| Known as | rineterkib | “BACKGROUND: Genetic alterations activating the MAPK pathway are common in non-small cell lung cancer (NSCLC). Patients with NSCLC may benefit from treatment with the pan-RAF...” PMID 39383771 ↗ Sep 2024 |
| Action | Inhibit | “ERK Inhibitor” NCT02711345 ↗ |
| Route | Oral | “A Phase I Dose Finding Study of Oral LTT462 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.” NCT02711345 ↗ |